Journal
JOURNAL OF VIROLOGY
Volume 83, Issue 20, Pages 10358-10365Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/JVI.01073-09
Keywords
-
Categories
Funding
- AIDS Research and Reference Reagent Program, Division of AIDS (DAIDS)
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health
- Janet Harouse, Cecilia Cheng-Mayer, and Ranajit Pal.
- [RR00165]
Ask authors/readers for more resources
New-generation gels that deliver potent antiretroviral drugs against human immunodeficiency virus type 1 have renewed hopes for topical prophylaxis as a prevention strategy. Previous preclinical research with monkey models suggested that high concentrations and drug combinations are needed for high efficacy. We evaluated two long-acting reverse transcriptase inhibitors, tenofovir (TFV) and emtricitabine (FTC), by using a twice-weekly repeat challenge macaque model and showed that a preexposure vaginal application of gel with 1% TFV alone or in combination with 5% FTC fully protected macaques from a total of 20 exposures to simian-human immunodeficiency virus SF162p3. FTC and TFV were detected in plasma 30 min after vaginal application, suggesting rapid absorption. FTC was detected more frequently than TFV and showed higher levels, reflecting the fivefold-higher concentration of this drug than of TFV. Two of 12 repeatedly exposed but protected macaques showed limited T-cell priming, which did not induce resistance to infection when macaques were rechallenged. Thus, single drugs with durable antiviral activity can provide highly effective topical prophylaxis and overcome the need for noncoital use or for drug combinations which are more complex and costly to formulate and approve.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available